🇺🇸 FDA
Patent

US 10316031

Compositions and methods for inhibiting kinases

granted A61KA61K2300/00A61K31/506

Quick answer

US patent 10316031 (Compositions and methods for inhibiting kinases) held by Inhibikase Therapeutics, Inc. expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibikase Therapeutics, Inc.
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2300/00, A61K31/506, A61K45/06, A61P